Germany reports more AstraZeneca clot cases
Germanys medical regulator says it has received reports of 21 cases of rare blood clots in people who had recently received AstraZenecas coronavirus vaccine.The Paul Ehrlich Institute said in an email Monday to The Associated Press that seven people affected by the blood clots have died.The incidence of an unusual form of blood clot in the head, known as sinus vein thrombosis, prompted several European countries to temporarily halt the use of the AstraZeneca vaccine earlier this month.
- Country:
- Germany
Germany's medical regulator says it has received reports of 21 cases of rare blood clots in people who had recently received AstraZeneca's coronavirus vaccine.
The Paul Ehrlich Institute said in an email Monday to The Associated Press that seven people affected by the blood clots have died.
The incidence of an unusual form of blood clot in the head, known as sinus vein thrombosis, prompted several European countries to temporarily halt the use of the AstraZeneca vaccine earlier this month. After a review by medical experts. the European Union's medical regulator EMA recommended that warnings about possible rare side effects should be added to the vaccine information provided for patients and doctors.
Most EU countries have since resumed use of the vaccine.
The Paul Ehrlich Institute said that of the 21 cases reported in Germany until March 25, 12 also involved an abnormally low level of platelets in the patients' blood.
Of the 21 cases, 19 were in women ages 20 to 63, while two were in men ages 36 and 57.
During the period covered by the reports, some 2.27 million first doses of the AstraZeneca vaccine were administered in Germany.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Health News Roundup: AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer; US FDA issues warning letters to retailers against underage sale of ZYN nicotine pouches and more
BRIEF-AstraZeneca Says Imfinzi Improved OS & PFS In Limited-Stage SCLC
BRIEF-Astrazeneca Says All Resolutions Were Supported At Today's AGM
BRIEF-Astrazeneca To Increase 2024 Dividend By 7%
AstraZeneca shareholders approve 2024 pay policy at AGM